High Quality Content by WIKIPEDIA articles! ANA773 is an oral prodrug developed by Anadys Pharmaceuticals which forms an active metabolite that is an agonist for TLR7. It causes an induction of endogenous type 1 interferons. It is designed to treat Hepatitis C and is currently in phase IIa trials and results have shown it to be well tolerated and to have potent antiviral activity irrespective of viral genotype, viral load, gender or previous response to IFN based therapies.